Clinical and Translational Oncology

, Volume 14, Issue 6, pp 458–464 | Cite as

Trends in prostate cancer survival in Spain: results from population-based cancer registries

  • Rafael Marcos-Gragera
  • Diego Salmerón
  • Isabel Izarzugaza
  • Eva Ardanaz
  • Bernat-Carles Serdà
  • Nerea Larrañaga
  • Erkuden San Román
  • Carmen Navarro
  • María-Dolores Chirlaque
Research Articles



The aim of this study is to analyse the evolution of the survival of patients diagnosed with prostate cancer during the period 1995–2003.

Material and methods

This is a population survival study of incident cases of prostate cancer in four Spanish areas: Basque Country, Girona, Murcia and Navarra. We calculated the relative survival (RS) at 5 years and its 95% confidence intervals using a cohort analysis and adjusted for age. To assess the trend in survival between the periods (1995–1999 and 2000–2003) a Poisson regression model was used, adjusting for age, region and period, obtaining the relative risk of death.


The number of patients diagnosed during the 1995–1999 period was 6493 and 8331 in the period 2000–03. The RS at 5 years adjusted for age increased significantly, from 75.3% (95% CI 73.3–77.2) in the period 1995–99 to 85% (95% CI 83.4–86.4) in the period 2000–03.


In Spain the survival of patients with prostate cancer has increased significantly from 1999 to 2003, probably due to the advancement in diagnosis produced by the opportunistic screening of prostate-specific antigen (PSA). Differences in the dissemination and use of the PSA level could explain the observed geographic differences in the increase of survival. It would be necessary to carry out studies to quantify the produced overdiagnosis by screening with PSA in prostate cancer.


Prostate cancer Incidence Survival PSA Quality of life 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hankey BF, Feuer EJ, Clegg LX et al (1999) Cancer surveillance series: interpreting trends in prostate cancer part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017–1024PubMedCrossRefGoogle Scholar
  2. 2.
    Kvale R, Auvinen A, Adami HO et al (2007) Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99:1881–1887PubMedCrossRefGoogle Scholar
  3. 3.
    Larranaga N, Galceran J, Ardanaz E et al (2010) Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol 21[Suppl 3]:iii83–iii89PubMedCrossRefGoogle Scholar
  4. 4.
    Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548–552PubMedCrossRefGoogle Scholar
  5. 5.
    Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: populationbased estimates for the year 2000 by period analysis. J Clin Oncol 23:441–447PubMedCrossRefGoogle Scholar
  6. 6.
    Borras J, Marcos-Gragera R, Torres A, Espinas JA (2008) [Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: prostate cancer]. Med Clin (Barc) 131[Suppl 1]:63–66CrossRefGoogle Scholar
  7. 7.
    Galceran J, Puigdefabregas A, Ribas G et al (2008) Cancer survival trends in Catalonia and comparison with Europe. Med Clin (Barc) 131[Suppl 1]:19–24CrossRefGoogle Scholar
  8. 8.
    Etzioni R, Penson DF, Legler JM et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981–990PubMedCrossRefGoogle Scholar
  9. 9.
    Merrill RM, Wiggins CL (2002) Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 7:213–219PubMedCrossRefGoogle Scholar
  10. 10.
    Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53:171–184PubMedCrossRefGoogle Scholar
  11. 11.
    Collin SM, Martin RM, Metcalfe C et al (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 9: 445–452PubMedCrossRefGoogle Scholar
  12. 12.
    Bray F, Lortet-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46:3040–3052PubMedCrossRefGoogle Scholar
  13. 13.
    Cayuela A, Rodriguez-Dominguez S, Martin VE, Candau BR (2008) Recent changes in prostate cancer mortality in Spain. Trends analysis from 1991 to 2005. Actas Urol Esp 32:184–189PubMedCrossRefGoogle Scholar
  14. 14.
    Verdecchia A, Guzzinati S, Francisci S et al (2009) Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 45:1042–1066PubMedCrossRefGoogle Scholar
  15. 15.
    Chirlaque MD, Salmeron D, Ardanaz E et al (2010) Cancer survival in Spain: estimate for nine major cancers. Ann Oncol 21[Suppl 3]:iii21–iii29PubMedCrossRefGoogle Scholar
  16. 16.
    Curado MP, Edwards B, Shin HR et al (eds) (2007) Cancer incidence in five continents, vol. IX. IARC, LyonGoogle Scholar
  17. 17.
    Navarro C, Martos C, Ardanaz E et al (2010) Population-based cancer registries in Spain and their role in cancer control. Ann Oncol 21[Suppl 3]:iii3–13PubMedCrossRefGoogle Scholar
  18. 18.
    Martos MC, Saurina C, Feja C et al (2009) Accurately estimating breast cancer survival in Spain: cross-matching local cancer registries with the National Death Index. Rev Panam Salud Publica 26:51–54PubMedCrossRefGoogle Scholar
  19. 19.
    Navarro C (2006) The National Death Index: a largely expected advance in the access to mortality data. Gac Sanit 20:421–423PubMedCrossRefGoogle Scholar
  20. 20.
    Ferlay J, Burkhard S, Whelan S, Parkin DM (2005) Check and conversion programs for cancer registries (IARC/IACR Tools for Cancer Registries in Europe). IARC, LyonGoogle Scholar
  21. 21.
    de Angelis R, Francisci S, Baili P et al (2009) The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 45:909–930PubMedCrossRefGoogle Scholar
  22. 22.
    Frit A, Jack A, Percy C et al (2000) International Classification of Diseases for Oncology, 3rd edn. World Health Organisation, GenevaGoogle Scholar
  23. 23.
    Cancer Survival Group (2011) Strel Computer Program Version V 6.0 for Cancer Survival Analysis. (7 June 2011, date last accessed)Google Scholar
  24. 24.
    Esteve J, Benhamou E, Croasdale M, Raymond L (1990) Relative survival and the estimation of net survival: elements for further discussion. Stat Med 9:529–538PubMedCrossRefGoogle Scholar
  25. 25.
    Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40:2307–2316PubMedCrossRefGoogle Scholar
  26. 26.
    Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRefGoogle Scholar
  27. 27.
    Anonymous (2007) StataCorp. Stata Statistical Software: Release 10. StataCorp LP, TXGoogle Scholar
  28. 28.
    Sanchez MJ, Payer T, De Angelis R et al (2010) Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol 21[Suppl 3]:iii30–iii36CrossRefGoogle Scholar
  29. 29.
    Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975–2978PubMedCrossRefGoogle Scholar
  30. 30.
    Draisma G, Etzioni R, Tsodikov A et al (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101:374–383PubMedCrossRefGoogle Scholar
  31. 31.
    Coleman MP, Quaresma M, Berrino F et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730–756PubMedCrossRefGoogle Scholar
  32. 32.
    Jonler M, Eddy B, Poulsen J (2005) Prostatespecific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 39:214–218PubMedCrossRefGoogle Scholar
  33. 33.
    Andren O, Garmo H, Mucci L et al (2009) Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 100:170–173PubMedCrossRefGoogle Scholar
  34. 34.
    Bangma CH, Roemeling S, Schroder FH (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25:3–9PubMedCrossRefGoogle Scholar
  35. 35.
    Flamand V, Zini L, Salleron J et al (2008) Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004. Prog Urol 18:53–59PubMedCrossRefGoogle Scholar
  36. 36.
    Vutuc C, Waldhoer T, Madersbacher S et al (2001) Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev 10:425–428PubMedCrossRefGoogle Scholar
  37. 37.
    Sandblom G, Varenhorst E, Rosell J et al (2011) Randomised prostate cancer screening trial: 20 year follow-up. BMJ 342:d1539PubMedCrossRefGoogle Scholar
  38. 38.
    Pashayan N, Duffy SW, Pharoah P et al (2009) Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 100:1198–1204PubMedCrossRefGoogle Scholar
  39. 39.
    Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320–1328PubMedCrossRefGoogle Scholar
  40. 40.
    Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101:1325–1329PubMedCrossRefGoogle Scholar
  41. 41.
    Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725–732PubMedCrossRefGoogle Scholar
  42. 42.
    Harlan LC, Potosky A, Gilliland FD et al (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93:1864–1871PubMedCrossRefGoogle Scholar
  43. 43.
    van Leeuwen PJ, Connolly D, Gavin A et al (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46:377–383PubMedCrossRefGoogle Scholar
  44. 44.
    Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613PubMedCrossRefGoogle Scholar
  45. 45.
    Namiki S, Arai Y (2010) Health-related quality of life in men with localized prostate cancer. Int J Urol 17:125–138PubMedCrossRefGoogle Scholar
  46. 46.
    Ponholzer A, Brossner C, Struhal G et al (2006) Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol 24:325–330PubMedCrossRefGoogle Scholar
  47. 47.
    Voerman B, Fischer M, Visser A et al (2006) Health-related quality of life in Dutch men with prostate cancer. J Psychosoc Oncol 24:49–64PubMedCrossRefGoogle Scholar
  48. 48.
    Johansson JE, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719PubMedCrossRefGoogle Scholar
  49. 49.
    Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101PubMedCrossRefGoogle Scholar
  50. 50.
    Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685–1692PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2012

Authors and Affiliations

  • Rafael Marcos-Gragera
    • 1
    • 2
    • 5
  • Diego Salmerón
    • 2
    • 3
    • 4
  • Isabel Izarzugaza
    • 6
  • Eva Ardanaz
    • 2
    • 7
  • Bernat-Carles Serdà
    • 5
  • Nerea Larrañaga
    • 2
    • 8
  • Erkuden San Román
    • 7
  • Carmen Navarro
    • 2
    • 3
    • 4
  • María-Dolores Chirlaque
    • 2
    • 4
  1. 1.Unitat d’Epidemiologia i Registre de Càncer de Girona (UERCG) Pla Director d’Oncologia Departament de SalutInstitut d’Investigació Biomèdica de Girona (IdIBGi)GironaSpain
  2. 2.Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología y Salud Pública [CIBERESP])MadridSpain
  3. 3.Departamento de Ciencias SociosanitariasFacultad de MedicinaMurciaSpain
  4. 4.Registro de Cáncer de Murcia Servicio de EpidemiologíaConsejería de SanidadMurciaSpain
  5. 5.Departamento de EnfermeríaUniversidad de GironaGironaSpain
  6. 6.Departamento Sanidad Gobierno VascoRegistro de Cáncer de EuskadiVitoria-GasteizSpain
  7. 7.Registro de Cáncer de NavarraInstituto de Salud Pública de NavarraPamplona, NavarraSpain
  8. 8.Registro de Cáncer de EuskadiSubdirección de Salud Pública de GipuzkoaDonostia-San Sebastián, GuipúzcoaSpain

Personalised recommendations